By
Ruth Prickett2024-03-26T14:00:00
Organizations with property in the European Union should be asking more questions about their sustainability and emissions in light of revised plans to decarbonize buildings across the region.
Buildings currently cause 40 percent of the EU’s energy consumption and produce 36 percent of its greenhouse gas emissions. The Energy Performance of Buildings Directive (EPBD), revisions to which were agreed to by European Parliament earlier this month, sets targets for all new buildings to create zero emissions by 2030.
Existing nonresidential buildings with the highest emissions will need to be renovated, beginning by 2030. Fossil fuel heating and cooling systems will be phased out by 2040, and member states will be expected to install solar power in public and nonresidential buildings, “if technically and economically suitable.”
2024-03-20T16:03:00Z By Aaron Nicodemus
Legal experts are advising their public company clients to move forward with plans to comply with the SEC’s climate-related disclosure rule, despite lawsuits and other challenges being brought against the controversial policy in the aftermath of its approval.
2024-03-18T14:57:00Z By Ruth Prickett
The future of the EU’s Corporate Sustainability Due Diligence Directive was thrown into doubt when the European Council failed to endorse proposals. The directive is back on track after being agreed upon, albeit in weaker form.
2024-03-15T19:27:00Z By Kyle Brasseur
Tanja Cuppen, chief risk officer of ABN AMRO, shared her view on the Dutch bank’s biggest risk focus areas and the accomplishments of her tenure a month ahead of her planned departure.
2025-12-10T15:30:00Z By Neil Hodge
For the past decade, Europe has led in creating strong but flexible rules for data use and safe AI development. The EU’s new plans to simplify key data privacy and AI governance measures have received a mixed response.
2025-12-05T19:25:00Z By Oscar Gonzalez
The U.S. Securities and Exchange Commission’s (SEC) Division of Examinations released its 2026 examination priorities, which give companies a roadmap of areas of heightened risk and regulatory focus for next year.
2025-12-04T22:15:00Z By Ruth Prickett
Regulation is a matter of life and death in the pharmaceutical industry. Rules to combat practices that can kill have been in force for decades, but tech developments are rapidly creating new risks and focusing lawmakers’ attention on areas where some compliance teams may lack experience.
Site powered by Webvision Cloud